Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya
Executive Summary
The European Medicines Agency’s pharmacovigilance committee has recommended more restrictions on the use of Richter’s Esmya because of concerns over the risk of serious liver damage.
You may also be interested in...
EMA Safety Panel Recommends Withdrawing Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
EMA Safety Commission Recommends Withdrawal Of Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the EMA’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
EU Suspends Ulipristal Pending Further Review
Gedeon Richter's Esmya should not be prescribed to women while the European Medicines Agency again reviews the risk of serious hepatic injury.